Beam Therapeutics (BEAM) to Release Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is projected to release its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect Beam Therapeutics to post earnings of ($1.03) per share and revenue of $12.8250 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, August 5th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.04. Beam Therapeutics had a negative return on equity of 43.15% and a negative net margin of 661.31%.The company had revenue of $8.47 million for the quarter, compared to analysts’ expectations of $13.29 million. During the same quarter in the previous year, the business posted ($1.11) EPS. The business’s revenue for the quarter was down 28.0% on a year-over-year basis. On average, analysts expect Beam Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Beam Therapeutics Price Performance

NASDAQ:BEAM opened at $25.01 on Monday. Beam Therapeutics has a fifty-two week low of $13.52 and a fifty-two week high of $35.25. The stock’s 50-day moving average is $23.34 and its two-hundred day moving average is $20.09. The stock has a market cap of $2.53 billion, a PE ratio of -5.56 and a beta of 2.40.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its stake in shares of Beam Therapeutics by 113.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 31,888 shares of the company’s stock valued at $542,000 after acquiring an additional 16,935 shares in the last quarter. Rafferty Asset Management LLC raised its stake in shares of Beam Therapeutics by 2.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 122,832 shares of the company’s stock valued at $2,089,000 after acquiring an additional 2,961 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in shares of Beam Therapeutics in the 2nd quarter valued at approximately $765,000. Benjamin Edwards Inc. raised its stake in shares of Beam Therapeutics by 20.3% in the 2nd quarter. Benjamin Edwards Inc. now owns 31,656 shares of the company’s stock valued at $538,000 after acquiring an additional 5,342 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in shares of Beam Therapeutics by 468.3% in the 2nd quarter. Squarepoint Ops LLC now owns 138,765 shares of the company’s stock valued at $2,360,000 after acquiring an additional 114,349 shares in the last quarter. 99.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on BEAM. Cantor Fitzgerald raised Beam Therapeutics to a “strong-buy” rating in a research note on Monday, July 21st. Jefferies Financial Group assumed coverage on Beam Therapeutics in a research note on Thursday, October 9th. They set a “buy” rating and a $41.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Beam Therapeutics in a research note on Friday, October 10th. Barclays cut their price target on Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.92.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.